No overall impact on body mass index for age change after dolutegravir initiation in a French paediatric cohort.

Pierre FrangeVeronique Avettand-FenoelFlorence VeberStephane Blanche

Published in: HIV medicine (2022)

We found no evidence of change in BMIz in French children initiating dolutegravir. These reassuring findings maintain the primary position of dolutegravir among paediatric therapeutic options.

Keyphrases

hiv infected patients
antiretroviral therapy
body mass index
intensive care unit
emergency department
young adults